Acrivon Therapeutics, Inc. (ACRV)
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Acrivon Therapeutics, Inc. Common Stock
No splits on record
Nothing in ACRV's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - |
| Cost of Revenue | $1.36M | $1.01M | $536K | $0 | $0 | $13K |
| Gross Profit | -$1.36M | -$1.01M | -$536K | $0 | $0 | -$13K |
| Gross Margin | - | - | - | - | - | - |
| Research and Development | $59.99M | $63.99M | $45.49M | $23.95M | $13.72M | $1.87M |
| Selling, General, and Administrative | $24.12M | $25.21M | $21.21M | $8.71M | $2.47M | $1.3M |
| Other | -$1.36M | -$1.01M | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $82.76M | $88.19M | $66.7M | $32.66M | $16.18M | $3.17M |
| Operating Income (EBIT) | -$84.11M | -$89.2M | -$67.24M | -$32.66M | -$16.18M | -$3.17M |
| Operating Margin | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Interest Income | $6.48M | $9.2M | $7.04M | $0 | $0 | $0 |
| Other Income (Expense) | $6.21M | $8.64M | $6.85M | $1.49M | -$59K | -$2.14M |
| Income Before Tax (EBT) | -$77.91M | -$80.56M | -$60.39M | -$31.17M | -$16.24M | -$5.31M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | -$16.24M | -$5.31M |
| Net Income Margin | - | - | - | - | - | - |
| Supplementary Data | ||||||
| EPS | -2.02 | -2.10 | -2.74 | -1.42 | -1.26 | -0.41 |
| Diluted EPS | -2.02 | -2.10 | -2.74 | -1.42 | -1.26 | -0.41 |
| Weighted Average OS | 38.51M | 38.30M | 22.08M | 21.92M | 12.91M | 12.91M |
| EBITDA | -$76.55M | -$79.55M | -$59.85M | -$30.8M | -$16.21M | -$5.29M |
| EBITDA Margin | - | - | - | - | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Assets | ||||||
| Current Assets | ||||||
| Cash and Cash Equivalents | $41.5M | $39.82M | $36.02M | $29.52M | $99.6M | $1.58M |
| Short-Term Investments | $77.08M | $139.66M | $91.44M | $98.23M | $0 | $0 |
| Cash and Short-Term Investments | $118.58M | $179.48M | $127.46M | $127.75M | $99.6M | $1.58M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $1.86M | $2.15M | $2.23M | $4.34M | $0 | $0 |
| Total Current Assets | $120.44M | $181.63M | $129.69M | $132.09M | $100.41M | $1.72M |
| Long-Term Assets | ||||||
| Property, Plant & Equipment Net | $7.42M | $8.03M | $7.91M | $6.86M | $5.79M | $59K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $5.09M | $0 | $41.88M | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.86M | $1.84M | $665K | $388K | $388K | $407K |
| Total Long-Term Assets | $9.27M | $14.96M | $8.57M | $49.13M | $6.18M | $466K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $129.72M | $196.59M | $138.26M | $181.23M | $106.59M | $2.19M |
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts Payable | $2.28M | $758K | $5.05M | $904K | $964K | $136K |
| Short-Term Debt | $0 | $1.06M | $0 | $0 | $0 | $58K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $69K | $66K | $0 |
| Other Current Liabilities | $5.56M | $5.46M | $3.86M | $2.66M | $667K | $334K |
| Total Current Liabilities | $15.66M | $17.21M | $13.3M | $6.52M | $2.91M | $613K |
| Long-Term Liabilities | ||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | $122.52M | $9.98M |
| Total Long-Term Liabilities | $1.54M | $2.59M | $3.77M | $4.24M | $127.48M | $9.98M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $17.2M | $19.8M | $17.07M | $10.75M | $130.4M | $10.6M |
| Stockholders' Equity | ||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $31K | $31K | $23K | $22K | $2K | $1K |
| Retained Earnings | -$274.88M | -$196.98M | -$116.42M | -$56.03M | -$24.86M | -$8.62M |
| Comprehensive Income & Other | $111K | $447K | -$83K | -$95K | $0 | $0 |
| Other Stockholders' Equity | $387.37M | $373.73M | $237.59M | $226.49M | $1.05M | $208K |
| Total Equity | $112.52M | $176.79M | $121.19M | $170.47M | -$23.81M | -$8.41M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $129.72M | $196.59M | $138.26M | $181.23M | $106.59M | $2.19M |
| Supplementary Data | ||||||
| Total Debt | $2.71M | $3.65M | $4.64M | $4.96M | $5.63M | $58K |
| Net Debt | -$38.79M | -$36.17M | -$31.37M | -$24.56M | -$93.97M | -$1.52M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Operating Activities | ||||||
| Net Income | -$77.91M | -$80.56M | -$60.39M | -$31.17M | -$16.24M | -$5.31M |
| Depreciation & Amortization | $1.36M | $1.01M | $536K | $364K | $37K | $13K |
| Deferred Income Tax | $0 | $0 | -$3.61M | $0 | $0 | $0 |
| Stock-Based Compensation | $14.72M | $14.29M | $11.62M | $2.19M | $497K | $3K |
| Changes in Working Capital: | ||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $1.54M | -$3.59M | $3.61M | -$245K | $798K | $81K |
| Other Working Capital | -$3.96M | $6.02M | $4.53M | -$1.29M | -$470K | $236K |
| Total Working Capital Change | -$2.43M | $2.44M | $8.14M | -$1.53M | $328K | $317K |
| Other Non-Cash Items | $590K | -$2.85M | $1.06M | $33K | $1.4M | $2.17M |
| Net Cash from Operating | -$63.66M | -$65.67M | -$42.64M | -$30.12M | -$13.98M | -$2.8M |
| Investing Activities | ||||||
| Capital Expenditures | -$1.67M | -$2.77M | -$1.29M | -$2.17M | -$238K | -$15K |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$81.73M | -$202.93M | -$56.53M | -$150.18M | $0 | $0 |
| Sales of Investments | $149.5M | $153.92M | $108.53M | $10.67M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $66.1M | -$51.77M | $50.72M | -$141.68M | -$238K | -$15K |
| Financing Activities | ||||||
| Debt Repaid | - | - | - | - | - | - |
| Common Stock Issuance | $1K | $70M | -$257K | $104.46M | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$750K | $51.03M | -$1.3M | -$2.75M | $1K | $0 |
| Net Cash from Financing | -$749K | $121.03M | -$1.55M | $101.71M | $112.22M | $2.89M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $1.69M | $3.59M | $6.52M | -$70.08M | $98M | $71K |
| Supplementary Data | ||||||
| Operating Cash Flow | -$63.66M | -$65.67M | -$42.64M | -$30.12M | -$13.98M | -$2.8M |
| Capital Expenditure | -$1.67M | -$2.77M | -$1.29M | -$2.17M | -$238K | -$15K |
| Free Cash Flow | -$65.33M | -$68.44M | -$43.93M | -$32.28M | -$14.22M | -$2.82M |
| Cash at Beginning | $40.02M | $36.43M | $29.91M | $99.99M | $1.99M | $1.92M |
| Cash at End | $41.7M | $40.02M | $36.43M | $29.91M | $99.99M | $1.99M |